QTc-prolongation in the use of antidepressants for anxiety-disorders

Phase 4

Completed

• Conditions: Long QT syndrome; LQTS; 10007521

• Registration Number: NL-OMON38604
• Lead Sponsor: Parnassia (Den Haag)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

- Age between 18 and 55 years.
- Under treatment of the department of Anxiety Disorders, PsyQ, The Hague.
- Indication to start with antidepressant medication and not known to have a contra-indication to start with this kind of medication, e.g. severe liver dysfunction, long QT-syndrome, recent myocardial infarct.
- Able and willing to give informed consent.

Exclusion Criteria

- Patients who had used already antidepressant medication in the 6 weeks prior to the inclusion.
- Patients who already use QT-prolonging anti-arrhythmic medication (e.g. sotalol, amiodarone).
- Patients who do not meet inclusion-criteria.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameter is the incidence of QTc-prolongation caused by<br /><br>different types of antidepressants use, measured by the difference in QTc-time<br /><br>between baseline and after six weeks of antidepressant use within one person. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>We investigate whether there is a difference between the different types of<br /><br>antidepressants (serotonin-reuptake inhibitors, serotonine-noradrenaline<br /><br>reuptake inhibitors, tricyclic antidepressants, mono-amine oxidase inhibitors)<br /><br>on the prolongation of the QTc-interval. In addition we will investigate if<br /><br>there are specific risk factors that contribute to this prolongation.</p><br>